Clinical characteristics and survival of glioblastoma complicated with non-central nervous system tumors

Chen Wang, Di Wang, Changqing Pan, Jiazheng Zhang, Cheng Cheng, You Zhai, Mingchen Yu, Zhiliang Wang, Guanzhang Li, Wei ZhangChinese 2022 · DOI

Abstract

Implications for the non-central nervous system tumors on survival of glioblastomas were not found in this research. However, glioblastomas complicated with other malignant tumors still showed worse clinical outcomes.

Introduction

Glioblastoma (GBM) is the most aggressive primary brain tumor, presenting significant challenges in clinical management. Occasionally, clinicians encounter patients with multiple primary malignant neoplasms (MPMN), where GBM co-occurs with tumors in other systems, such as the breast, lungs, or reproductive organs. This study aims to determine whether the presence of these non-central nervous system (non-CNS) tumors impacts the clinical characteristics, molecular profiles, or survival outcomes of patients with IDH-wildtype glioblastoma.

Methods

Researchers conducted a retrospective cohort study focusing on isocitrate dehydrogenase (IDH) wild-type glioblastoma, the most common and aggressive form of the disease. The study group consisted of 45 patients from Beijing Tiantan Hospital (diagnosed between January 2019 and February 2022) who had both IDH-wildtype GBM and at least one non-CNS tumor. This group was compared against a matched control group of 112 patients with only IDH-wildtype GBM, sourced from the Chinese Glioma Genome Atlas (CGGA) 325 database. The analysis included clinical features, molecular markers such as TERT promoter mutations and MGMT methylation, and survival outcomes using Kaplan-Meier estimates and univariate Cox proportional hazard regression models.

Results

Clinical and Molecular Characteristics

The study identified a notable gender bias, with female patients comprising 77.8% of the group with multiple primary tumors. The most common secondary tumors were related to the reproductive system, specifically breast tumors and hysteromyomas (uterine fibroids). Patients with multiple tumors tended to be older at the time of GBM diagnosis (median age 56 vs. 53.5 years).

Molecular analysis revealed that patients with multiple tumors had a significantly higher frequency of TERT promoter mutations (68.4% vs. 47.0%). TERT mutations are generally associated with poorer outcomes in gliomas, suggesting a distinct genetic profile in this patient subgroup.

Survival Outcomes

Overall, the presence of a non-CNS tumor did not result in a statistically significant difference in survival compared to the GBM-only group (23.9 months vs. 27.8 months, p=0.701). However, the malignancy of the secondary tumor proved to be a critical factor. Within the study group, patients with benign secondary tumors had a median overall survival (OS) of 32.06 months, while those with malignant secondary tumors had a significantly shorter median OS of 22.83 months (p=0.026).

Furthermore, univariate analysis confirmed that postoperative adjuvant therapy (chemotherapy and radiotherapy) remains the strongest predictor of survival, regardless of whether the patient has other tumors.

Discussion and Conclusion

While the mere presence of a secondary non-CNS tumor does not necessarily worsen the prognosis for GBM patients, the malignancy of that secondary tumor is a significant negative prognostic indicator. The higher prevalence of TERT promoter mutations in these patients suggests a potential genetic predisposition toward multi-organ tumor formation.

These findings suggest that patients with benign secondary tumors should not necessarily be excluded from GBM clinical trials based on their comorbidity. However, the study's limitations, including a small sample size and retrospective design, highlight the need for larger, multi-center studies and deeper genomic sequencing to uncover the innate mechanisms driving multiple primary tumors in these patients.

Summary updated

Abstract

Implications for the non-central nervous system tumors on survival of glioblastomas were not found in this research. However, glioblastomas complicated with other malignant tumors still showed worse clinical outcomes.
BibTeX
@inproceedings{wang2022clinical,
  author = {Chen Wang and Di Wang and Changqing Pan and Jiazheng Zhang and Cheng Cheng and You Zhai and Mingchen Yu and Zhiliang Wang and Guanzhang Li and Wei Zhang},
  title = {{Clinical characteristics and survival of glioblastoma complicated with non-central nervous system tumors}},
  booktitle = {Chinese},
  year = {2022},
  doi = {10.1186/s41016-022-00312-1},
}
Figure